Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in DO NOT EDIT

3 clinical trials in DO NOT EDIT, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
DO NOT EDIT at a glance
3
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

3 trials in DO NOT EDIT

Open in trial search

Dermatomyositis+2

Recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Pfizer Inc.

Systemic lupus erythematosus

Not yet recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Benzocaine
  • Sponsor:UCB Biopharma

Diffuse large B-cell lymphoma

Not yet recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Sweden

The busiest research cities in the country

All 65 cities in Sweden

Clinical research in DO NOT EDIT

What the registry says about research in the country

01 DO NOT EDIT
Hemic and Lymphatic Diseases
A trial is evaluating whether adding epcoritamab to the standard R‑mini‑CHOP regimen can improve outcomes for newly diagnosed Diffuse large B‑cell lymphoma patients who are elderly, frail, or unfit. Combination immunotherapy with epcoritamab Optimizing treatment for frail lymphoma patients Comparing efficacy against standard chemo alone Enhancing survival in elderly DLBCL cases The study is actively recruiting in the Swedish city, aiming to expand therapeutic options for vulnerable lymphoma patients.
Immune System Diseases
The study assesses the long‑term safety of dazukibart in individuals with Idiopathic inflammatory myopathy, including dermatomyositis and polymyositis. Long‑term safety monitoring Open‑label extension after parent study Impact on muscle inflammation control Systematic adverse‑event tracking This investigator‑led effort is currently open for enrollment, offering participants a chance to contribute to future immune‑targeted therapies.
Musculoskeletal Diseases
Research in the musculoskeletal field examines how targeted therapy can stabilize muscle inflammation and function in Idiopathic inflammatory myopathy patients. Muscle strength and stamina outcomes Quality‑of‑life assessments Biomarker discovery for disease activity Integration of physical therapy with drug treatment The project reflects a collaborative approach between clinicians and rehabilitation specialists in the region.
Neoplasms
In the neoplasm arena, investigators are testing a novel antibody approach to boost the efficacy of standard chemo in Diffuse large B‑cell lymphoma. Targeted antibody enhancement of chemo Tailored therapy for elderly cancer patients Survival benefit analysis Integration with existing treatment protocols This pioneering work seeks to set new standards for lymphoma care within the local research community.
Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.